IGF-1 and IGF-Binding Proteins and Bone Mass, Geometry, and Strength: Relation to Metabolic Control in Adolescent Girls With Type 1 Diabetes

Laurie J Moyer-Mileur,1 Hillarie Slater,1 Kristine C Jordan,1,2 and Mary A Murray3

ABSTRACT: Children and adolescents with poorly controlled type 1 diabetes mellitus (T1DM) are at risk for decreased bone mass. Growth hormone (GH) and its mediator, IGF-1, promote skeletal growth. Recent observations have suggested that children and adolescents with T1DM are at risk for decreased bone mineral acquisition. We examined the relationships between metabolic control, IGF-1 and its binding proteins (IGFBP-1, -3, -5), and bone mass in T1DM in adolescent girls 12–15 yr of age with T1DM (n = 11) and matched controls (n = 10). Subjects were admitted overnight and given a standardized diet. Periodic blood samples were obtained, and bone measurements were performed. Serum GH, IGFBP-1 and -5, glycosylated hemoglobin (HbA1c), glucose, and urine magnesium levels were higher and IGF-1 values were lower in T1DM compared with controls (p < 0.05). Whole body BMC/bone area (BA), femoral neck areal BMD (aBMD) and bone mineral apparent density (BMAD), and tibia cortical BMC were lower in T1DM (p < 0.05). Poor diabetes control predicted lower IGF-1 (r² = 0.21) and greater IGFBP-1 (r² = 0.39), IGFBP-5 (r² = 0.38), and bone-specific alkaline phosphatase (BALP; r² = 0.41, p < 0.05). Higher urine magnesium excretion predicted an overall shorter, lighter skeleton, and lower tibia cortical bone size, mineral, and density (r² = 0.44–0.75, p < 0.05). In the T1DM cohort, earlier age at diagnosis was predictive of lower IGF-1, higher urine magnesium excretion, and lighter, thinner cortical bone (r² ≥ 0.45, p < 0.01). We conclude that poor metabolic control alters the GH/IGF-1 axis, whereas greater urine magnesium excretion may reflect subtle changes in renal function and/or glucosuria leading to altered bone size and density in adolescent girls with T1DM.

J Bone Miner Res 2008;23:1884–1891. Published online on July 28, 2008; doi: 10.1359/JBMR.080713

Key words: metabolic control, bone, adolescence, diabetes

INTRODUCTION

Good bone health is important to the maintenance of functionality in the aging population. Pubertal bone mineral accretion is predictive of osteoporosis in aging women.1 Recent observations suggest that children and adolescents with type 1 diabetes mellitus (T1DM) are at risk for decreased bone mineral acquisition.2,6–7 Our research group has observed significantly lower bone mass in adolescents with T1DM compared with a nondiabetic reference population.8,9 Children and adolescents with poorly controlled T1DM are at risk for decreased bone mass. Disease duration,7,10 poor metabolic control,2,6,11,12 and diabetic complications such as retinopathy or neuropathy2,10 are reported to have a negative impact on bone mass, although others have found no relationship.13,14 Poor blood glucose control has been associated with lower bone mass in adults and adolescents with T1DM8–11 but not in children.13,14

The growth hormone (GH)/IGF axis is a major determinant of bone mass acquisition. Circulating IGF-1 is produced by the liver, is structurally similar to insulin,15 and helps to mediate the skeletal growth promoting actions of GH. IGF-1 is also produced locally by muscle and bone tissue, where it is hypothesized to act in a paracrine manner. Along with systemic GH and estradiol, local bone IGF-1 concentrations are regulated by PTH, 1,25-dihydroxyvitamin D₃, and other cytokines and growth factors.16 IGF-1 functions as a key anabolic regulator of bone cell activity by decreasing collagen degradation and increasing bone matrix deposition and osteoblastic cell recruitment.17,18 In healthy children, serum IGF-1 concentrations correlate well with BMC.18 In adolescents with poorly controlled T1DM, there is established evidence of increased secretion of GH but low levels of IGF-1 compared with matched controls.13,17 Thus, the GH/IGF axis has received considerable attention as a mechanism for inadequate bone formation in T1DM.19–22

IGF binding proteins (IGFBPs) control the tissue availability of IGF-1 and therefore are major regulators of IGF-1 action. IGFBP-3 is the predominant circulating IGFBP, binding >95% of circulating IGF. Production of IGFBP-3 is stimulated by GH, whereas IGFBP-1 is in-
creased in the absence of GH. In patients with osteoporosis, IGFBP-1 and IGFBP-4 inhibit IGF bone cell proliferation by sequestering IGF-1 and preventing binding to the IGF receptor. IGFBP-3 and IGFBP-5 facilitate IGF action in bone cells: bone matrix proteoglycans do not bind IGFs in the absence of IGFBP-3 and IGFs do not bind to hydroxypatite in the absence of IGFBP-5. There is also some evidence that IGFBPs regulate bone formation independent of IGF function. For example, IGFBP-5 has been found to stimulate markers of bone formation in osteoblasts that lack functional IGF.

There is a paucity of information on how IGF-1 and IGFBPs regulate skeletal growth in children with T1DM during puberty. The purpose of this study was to assess the GH/IGF axis and bone health in adolescent girls with T1DM. A secondary objective was to examine the relationships between IGF-1 and its binding proteins and the characteristics and markers of bone turnover. We tested the central hypothesis that T1DM is associated with a state of partial GH resistance resulting in decreased IGF action and altered IGFBP activity, leading to diminished bone size, density, and strength.

**MATERIALS AND METHODS**

**Subjects**

Girls 12–15 yr of age with T1DM for a minimum of 12 mo (n = 11) were recruited from the Utah Diabetes Center Pediatric Program, Salt Lake City, UT, USA. Healthy girls matched for race, age, and maturation were recruited as controls (n = 10). Exclusion criteria included poor metabolic control (glycosylated hemoglobin [HbA1c] > 9.0%), hypertension (diastolic blood pressure > 90th percentile for age), microalbuminuria, hypo- or hyperthyroidism, GH deficiency, celiac disease (TG ≥7.0 AU or symptoms) or other health conditions or medication use known to alter growth or bone mineral deposition. This study was approved by the University of Utah Institutional Review Board for Human Subjects.

**Protocol**

The schema for the protocol is shown in Fig. 1. Potential subjects were evaluated in a prestudy visit. Appropriate subjects were admitted to the General Clinical Research Center (GCRC) at 4:00 p.m. on the day of study. Written informed consent and assent were obtained at admission. An intravenous catheter was placed in a forearm vein for blood access by 10:00 p.m., and blood samples were obtained from 11:00 p.m. to 11:00 a.m. First and second morning voids of urine were collected at 6:00 and 8:00 a.m. Subjects were given standardized meals and snacks with energy based on the subject’s sex, age, and body weight and a substrate distribution of 15% protein, 35% fat, and 50% carbohydrate. T1DM subjects received their usual insulin dose.

Each study participant completed a health history questionnaire, which included a family and personal medical history and current medication use. Pubertal maturation was determined by a pediatric endocrinologist using Tanner stage criteria. Calcium intake and past-year physical activity were also assessed by questionnaire. Metabolic hours of weight-bearing physical activity for the previous year were calculated by assigning each weight-bearing activity a number representing metabolic cost (MET). Height without shoes was measured to the nearest 0.1 cm for each participant using a Height-Rite Stadiometer (Model 225; Seca, Culver City, CA, USA), and weight was measured to the nearest 0.1 kg by digital scale (Model 5002; Scan-Tronix, Carol Stream, IL, USA). Body mass index (BMI, kg/m²) was calculated for all subjects.

**Bone measurements**

Three cross-sectional slices of the nondominant tibia were measured by pQCT (XCT-2000; Stratec/Orthometrix, White Plains, NJ, USA) at relative distances of 4%, 38%, and 66% from the distal tibia growth plate to assess trabecular and cortical bone and the muscle cross-sectional area (CSA), respectively. Dominance and nondominance were determined by asking whether the subject was right or left handed. Tibia metaphyseal bone properties, including trabecular volumetric BMD (vBMD; mg/cm³), were assessed from the 4% CSA. The 38% CSA was used to assess tibia diaphyseal bone properties, including cortical bone vBMD, BMC (mg), and geometric bone properties: bone CSA (mm²), cortical CSA (bone CSA less marrow CSA), marrow CSA (bone CSA less cortical CSA), and cortical thickness (mm). Muscle CSA and the polar strain strength index (pSSI, mm²) were determined from the 66% distal cross-section to examine bone muscle relationship and bone strength. Analysis parameters and modes were as previously described. In addition, whole body bone area (BA, cm²), BMC (g), lean body mass (LBM, kg), percent body fat, femoral neck (FN) and lumbar spine (LS) BA, BMC, and areal BMD (aBMD, g/cm²) were determined by DXA (4500A; Hologic, Waltham, MA, USA). Height for age, whole body BA to height, and whole body BMC to BA.
were assessed to determine whether bone mass was reduced because of short, narrow, or lighter bones. FN and LS BMC and BA values were used to determine bone mineral apparent density (BMAD, g/cm²). The CV for repositioning in adult volunteers was <2.5% for trabecular and cortical bone vBMD using pQCT and <1.0% for aBMD measured by DXA in our laboratory. The daily CVs for calibration phantoms were 0.1% and 0.3% for pQCT and DXA, respectively. The same experienced radiology technician performed all measurements. Although radiation exposure was minimal (~21.5 μSv total), pregnancy tests were performed before densitometry on all girls with Tanner stage ≥2.

Biochemical measures

GH, IGF-1, insulin, and glucose levels were determined from samples obtained hourly from 11:00 p.m. to 6:00 a.m. and IGF-1 and IGFBP-1 from 6:00 a.m. to 10:00 a.m. The area under the curve (AUC) was calculated for 11:00 p.m. to 6:00 a.m. values to assess the GH/IGF axis activity and between 9:00 and 10:00 a.m. to examine postprandial differences between IGF-1 and IGFBP-1. IGFBP-3, -4, and -5 values. All other serum values were determined from the fasting 8:00 a.m. blood sample. Pyridinoline (Pyd), deoxypyridinoline (DPd), and hydroxylysine-derived cross-links of mature collagen degradation were selected to indirectly assess bone resorption. Pyd and DPd cross-links were measured from the 6:00 a.m. urine sample, whereas calcium, phosphorus, magnesium, and creatinine assays were determined on the 8:00 a.m. sample. Serum samples (10 ml) were collected using a standard technique from indwelling catheters without anticoagulants and were processed to avoid hemolysis. Serum was separated by centrifugation and stored at −70°C until analysis. Urine samples were collected without preservative and stored at −70°C. ELISA assays were used to measure GH, IGF-1, IGFBP-1, -3, and -4, insulin, 1,25(OH)2 vitamin D (DSL), and bone-specific alkaline phosphatase (BALP; Metra); high performance liquid chromatography (HPLC) was used to measure HbA1c; and the spectrophotometric technique was used to measure serum and urine minerals. IGFBP-5 levels were measured by the Musculoskeletal Disease Center Laboratory, Loma Linda University, using polyclonal guinea pig antisera and recombinant IGFBP-5 as standard and tracer, respectively. Pyd and DPd were measured by HPLC, with standards purchased from Quidel (San Diego, CA, USA). Urinary Pyd cross-link concentration was normalized to urinary creatinine (Beckman Creatinine Analyzer 2) and calculated as μmol/mol creatinine. Measurements were made in duplicate, and the average values were entered into the database.

Statistical methods

Statistical analyses included independent t-test and χ² to identify differences in demographic variables of interest between T1DM and control subjects. Standard deviation scores (SDSs) were generated for body weight and height using EpiInfo. The ratios of IGFBP-1, -3, -4, and -5 to IGF-1 were calculated. Multivariate and repeated-measures analysis of covariance (MANCOVA) and posthoc tests were used to compare means between T1DM and control groups for blood and urine results, bone measurements, and body composition using pubertal stage and height SDS as covariates. Bone results are reported as adjusted means with the 5th and 95th CIs. Correlation analysis was run between selected continuous variables. Stepwise linear regression was performed to identify which variable predicted biochemical and bone characteristics. Statistical analyses for these data were performed using the SPSS-PC+ (Version 13.1; SPSS) statistical software program with significance set at p < 0.05.

RESULTS

Demographic data are presented in Table 1. Age, pubertal maturation, body size and composition, reported calcium intake, and physical activity levels were similar between groups.

Biochemical findings

GH/IGF-1 axis results were as expected (Table 2). The rise in GH levels was greater at 12:00 p.m. and 1:00 a.m. and the IGF-1 response was lower in T1DM girls compared with controls (p < 0.05; Fig. 2). The mean AUC values for GH and IGF-1 from 11:00 p.m. to 6:00 a.m., however, were not statistically significant. The mean hourly values for serum insulin and glucose at 12:00 p.m. to 6:00 a.m. were significantly higher in T1DM girls (p < 0.05) than controls. The mean hourly postprandial values for IGF-1 and IGFBP-1 are plotted in Fig. 3. Differences are again evident with lower mean IGF-1 and higher IGFBP-1 values found in the T1DM cohort compared with controls at 8:00, 9:00,
Urine polecally significant (relative to IGF-1, however, were higher in T1DM girls, similar (Table 2). The ratios for IGFBP-1, -3, -4, and -5 Serum Skeletal characteristics

The whole body, FN, LS, and tibial bone geometry, density, and strength findings for T1DM and control groups are presented in Table 3. Whole body BMC/BA and FN aBMD and BMAD values were significantly lower in T1DM girls \( (p \leq 0.05). \) The evaluation of tibial bone geometry and density showed significantly lower cortical BMC and cortical BMC/muscle CSA \( (p < 0.05), \) with a trend toward thinner cortical bone thickness and vBMD \( (p = 0.07 \) and 0.09, respectively) in T1DM girls. All other skeletal findings were similar between groups.

**Predictors**

Poor metabolic control predicted lower IGF-1 AUC values, contributing 50–94% of the total variability in fasting and postprandial levels, respectively \( (p \leq 0.01). \) Poor metabolic control was also correlated with higher IGFBP-1 and -5/IGF-1 ratios \( (R = 0.84, p \leq 0.05) \), but was not a significant predictor for either IGFBP-1 or -5 in the regression model. Greater urine magnesium excretion was predictive of a higher IGFBP-3/IGF-1 ratio, accounting for 26% of the variability \( (p = 0.001). \) The onset of menses was predictive of a higher IGFBP-4/IGF-1 ratio \( (r^2 = 0.23, p = 0.001). \) The absence of menses, higher serum 25(OH) vitamin D levels, and poor metabolic control predicted higher levels of BALP \( (r^2 = 0.69, p = 0.001), \) accounting for 32%, 28%, and 9% of the variance, respectively. Higher 25(OH) vitamin D levels were predicted by higher BALP and lower GH levels, which accounted for 28% and 13% of variability, respectively. Higher 25(OH) vitamin D levels were predicted by higher BALP and lower GH levels, which accounted for 28% and 13% of variability, respectively. Higher serum glucose was the single predictor of greater bone resorption \( (r^2 = 0.48, p = 0.001) \) and urine magnesium excretion \( (r^2 = 0.61, p < 0.01), \) accounting for 48% and 61%, respectively, of the variability observed in Dpd/Pyd and urine magnesium levels.

The relationships between T1DM disease–related factors and biochemical findings were examined by removing control and adding age at diagnosis, disease duration, and insulin dose \( (U/kg/d) \) to the regression model. A younger age at diagnosis was predictive of lower IGF-1 and higher IGFBP-1/IGF-1 ratios and greater urine magnesium excretion, accounting for 79–97% of the variability. Poor metabolic control strongly correlated with the ratios of IGFBP-4 and 10:00 a.m. \( (p < 0.05). \) This finding is substantiated by lower IGF-1 and higher IGFBP-1 AUC values in T1DM girls from 8:00 to 10:00 a.m. \( (778.6 \pm 232.3 \text{ ng/dl} \ \text{IGF-1} \text{ and} 954.8 \pm 198.9 \text{ ng/dl} \ \text{IGFBP-1} \text{ T1DM versus} 89.65 \pm 6.01 \text{ ng/dl} \ \text{IGF-1} \text{ and} 258.6 \pm 110.0 \text{ ng/dl} \ \text{IGFBP-1} \text{ controls; } p \leq 0.05). \) The mean fasting levels for IGFBP-3, -4, and -5 were similar (Table 2). The ratios for IGFBP-1, -3, -4, and -5 relative to IGF-1, however, were higher in T1DM girls, although only IGFBP-1 and -5/IGF-1 ratios were statistically significant \( (p \leq 0.05; \text{data not shown}). \)

Additional serum and urine results are also presented in Table 2. T1DM girls had higher fasting HbA1c and serum glucose values versus controls \( (p \leq 0.01). \) The mean values for markers of bone turnover tended to be greater, as evidenced by higher serum BALP and urine Dpd/Pyd levels and lower mean 25(OH) vitamin D levels in T1DM girls. Urine magnesium levels were markedly higher in T1DM girls compared with controls \( (p < 0.05). \) We did not detect differences in serum PTH, calcium, magnesium, and phosphorus levels or urine calcium and phosphorus excretion. With the exception of serum HbA1c, glucose, and urine magnesium for T1DM, all values were within the normal reference range.

### Skeletal characteristics

The whole body, FN, LS, and tibial bone geometry, density, and strength findings for T1DM and control groups are presented in Table 3. Whole body BMC/BA and FN aBMD and BMAD values were significantly lower in T1DM girls \( (p \leq 0.05). \) The evaluation of tibial bone geometry and density showed significantly lower cortical BMC and cortical BMC/muscle CSA \( (p < 0.05), \) with a trend toward thinner cortical bone thickness and vBMD \( (p = 0.07 \) and 0.09, respectively) in T1DM girls. All other skeletal findings were similar between groups.

### Table 2. Serum and Urine Results*

|                      | T1DM (N = 11) | Control (N = 10) | p       | Reference range |
|----------------------|--------------|-----------------|---------|----------------|
| Serum                |              |                 |         |                |
| IGFBP-1 (ng/ml)      | 66.37 ± 30.61| 37.13 ± 24.18   | 0.02    | 20–200         |
| IGFBP-3 (ng/ml)      | 4.28 ± 1.49  | 4.74 ± 0.74     | 0.85    | 2.1–6.2        |
| IGFBP-4 (ng/ml)      | 388.31 ± 275.06 | 434.81 ± 288.29 | 0.47   | Not established |
| IGFBP-5 (ng/ml)      | 289.77 ± 40.45 | 261.00 ± 47.45 | 0.13    | 300–600        |
| HbA1c (%)            | 8.11 ± 1.04  | 4.94 ± 0.34     | 0.001   | 4–6%           |
| Glucose (mg/dl)      | 148.28 ± 60.17 | 89.65 ± 6.01    | 0.04    | 80–110         |
| BALP (U/liter)       | 173.27 ± 97.23 | 128.92 ± 99.44 | 0.18    | 125–275        |
| 25(OH) Vitamin D (ng/ml) | 14.67 ± 7.67 | 29.54 ± 8.50 | 0.001 | 20–57 |
| PTH (pg/ml)          | 37.61 ± 6.23  | 27.34 ± 7.02    | 0.31    | 15–75          |
| Calcium (mg/dl)      | 9.01 ± 0.71   | 8.95 ± 0.55     | 0.71    | 8.0–10.0       |
| Magnesium (mg/dl)    | 2.06 ± 0.49   | 2.24 ± 0.55     | 0.22    | 1.58–2.55      |
| Phosphorus (mg/dl)   | 4.27 ± 0.90   | 3.78 ± 0.45     | 0.22    | 2.7–4.5        |
| Urine                |              |                 |         |                |
| Creatinine (mg/dl)   | 63.82 ± 36.45 | 81.91 ± 47.45 | 0.54 | 22–89         |
| Dpd (μmol/mole creat) | 61.63 ± 21.94 | 46.38 ± 25.15 | 0.37 | 13–61         |
| Pyd (μmol/mole creat) | 221.05 ± 71.05 | 179.23 ± 82.83 | 0.44 | 81–267        |
| Dpd/Pyd (μmol/mole creat; μmol/mole creat)\( \times 10^{-2} \) | 27.61 ± 3.25 | 25.39 ± 3.01 | 0.09 | 17–27        |
| Calcium (mg/mg creat)\( \times 10^{-2} \) | 7.72 ± 5.41 | 7.72 ± 4.88 | 0.51 | 10–24         |
| Magnesium (mg/mg creat)\( \times 10^{-2} \) | 3.14 ± 1.69 | 2.21 ± 0.94 | 0.02 | 0.2–2.6 |
| Phosphorus (mg/mg creat)\( \times 10^{-2} \) | 45.07 ± 28.34 | 37.58 ± 22.91 | 0.86 | Not established |

Values are mean ± SD. Significance determined by Mann-Whitney.

*Blood samples obtained at 8:00 a.m. and urine samples at 6:00 p.m. (fasting).
and -5 to IGF-1 (R = 0.78 and 0.65, respectively, p < 0.01), but was only predictive of IGFBP-5/IGF in the regression model ($r^2 = 0.91, p = 0.001$), accounting for 72% of the variance.

The relationships between T1DM disease-related factors and skeletal findings were examined by removing control and adding age at diagnosis, disease duration, and insulin dose (U/kg/d) to the regression model. Longer disease duration was predictive of smaller whole body bone size and lower tibia total and cortical CSA, cortical BMC, and thickness ($r^2 \geq 0.65, p = 0.001$), accounting for 6.9–80% of the variance.

Higher urine magnesium excretion was predictive of a greater height deficit, lighter bones, decreased FN BMAD, lower tibia cortical bone CSA, thickness, BMC, and tibia marrow CSA ($r^2 = 0.26-0.84, p \leq 0.05$) and accounted for 26–60% of the variance. A larger ratio of IGFBP-1 relative to IGF-1 was predictive of smaller bones and accounted for 36% of the variability observed in the BA/height ratio ($p = 0.001$). Trabecular vBMD was inversely related to IGFBP-1 and -5/IGF-1 ratios ($r^2 = 0.40, p = 0.001$), accounting for 11% and 29% of the variance, respectively. Greater tibia bone strength (pSSI) was predicted by higher IGF-1 levels ($r^2 = 0.23, p = 0.001$).

**DISCUSSION**

To our knowledge, this is the first study directed at the relationship between metabolic control, GH/IGF-1 axis activity, and bone health in adolescent girls with T1DM. The altered nighttime GH/IGF axis activity observed in our study confirms the work of others. We also found signifi-
cantly higher IGFBP-1 and -5 levels and less overall bone mineral deposition in adolescent girls with T1DM compared with healthy matched controls. Metabolic control was the predominant predictor of GH/IGF-1 axis alterations, whereas higher urine magnesium excretion was the predominant predictor of whole body and cortical bone deficits.

During puberty, sex hormones induce an increase in the GH/IGF system to promote linear growth and bone expansion. As maturation progresses, bone turnover is reduced, which increases cortical bone thickness and strength. We showed an alteration in the GH/IGF system and a negative association between IGFBP-1 and bone size in adolescent girls with T1DM. Although only nighttime GH/IGF-1 axis activity was assessed in our study, daytime GH/IGF-1 axis activity mimics nighttime GH/IGF-1 axis activity and increases insulin resistance and exogenous insulin requirements in adolescent girls with T1DM. The significantly lower postmeal IGF-1 and higher IGFBP-1/IGF1 levels in the T1DM cohort also suggest that GH/IGF-1 axis activity remains altered throughout the day.

Our group and others have previously reported skeletal deficits in adolescents with T1DM. In our previous work, lower whole body BMC, FN densities, trabecular vBMD values, and BMC acquisition were predicted by poor metabolic control. In animal and in vitro cell models, chronic hyperglycemia is linked to altered osteoblast differentiation and maturation. Recently, Thrailkill showed preservation of bone formation by insulin administration during osteogenesis in a mouse model. Neither insulin treatment nor glucose concentration, however, entirely explain lower bone mass in adolescents with T1DM.

In this study, adolescent girls with T1DM were matched for age, body size, and pubertal maturation with healthy controls. Both cohorts reported similar levels of dietary calcium intake and weight-bearing activities. We again observed significantly lower whole body BMC relative to BA and FN bone density and decreased cortical bone BMC relative to muscle in adolescent girls with T1DM. Furthermore, we noted a trend toward thinner tibia cortical thickness and decreased cortical vBMD in the T1DM cohort. Reduced radius cortical vBMD and total, cortical, and muscle CSA has been reported in children and adolescents diagnosed with T1DM before the age of 5. A strong negative association between an earlier manifestation of T1DM and smaller bone size and diminished BMC was also shown in our T1DM cohort.

Both FN aBMD and BMAD values were lower in our T1DM cohort compared with controls. Significantly lower size-adjusted FN and LS aBMD has recently been reported in adolescent and young adult women with T1DM and may explain, in part, the higher hip fracture incidence observed in adults with childhood onset T1DM. We did not detect, however, LS aBMD or BMAD deficits in our T1DM cohorts in our present or previous studies. Similar lumbar spine results have been found in children with recent onset of T1DM (<3 yr) and good metabolic control (HbA1c < 8.2%). The vertebrae, or lumbar spine, are primarily composed of trabecular bone, and decreased trabecular vBMD is associated with poor metabolic control. The absence of trabecular bone deficits in our T1DM cohort may be explained by restriction of enrollment to girls with HbA1c values of ≤9% for the year before study.

Overall metabolic control was not associated with skel-

### Table 3. Skeletal Characteristics

|                  | T1DM (N = 11) | Control (N = 10) | p     |
|------------------|---------------|------------------|-------|
| Whole body       |               |                  |       |
| BA/height (cm²/m)| 10.91 (10.09, 11.73) | 11.06 (10.14, 11.88) | 0.43  |
| BMC/BA (g/cm²)  | 0.81 (0.76, 0.86)   | 0.84 (0.79, 0.84)   | 0.01  |
| Femoral neck     |               |                  |       |
| aBMD (g/cm²)    | 0.85 (0.75, 0.92)   | 0.89 (0.78, 0.94)   | 0.05  |
| BMAD (g/cm³)    | 0.17 (0.15, 0.18)   | 0.18 (0.17, 0.20)   | 0.01  |
| Lumbar spine     |               |                  |       |
| aBMD (g/cm²)    | 0.84 (0.75, 0.92)   | 0.86 (0.78, 0.94)   | 0.21  |
| BMAD (g/cm³)    | 0.12 (0.11, 0.13)   | 0.12 (0.11, 0.13)   | 0.67  |
| Tibia            |               |                  |       |
| Geometry         |               |                  |       |
| Muscle CSA (mm²) | 5790.63 (5248.78, 6332.65) | 5420.26 (4870.24, 5962.28) | 0.11  |
| Total CSA (mm²)  | 308.02 (286.78, 329.26)  | 296.87 (296.92, 315.81)  | 0.26  |
| Cortical CSA     | 229.84 (208.12, 251.56)  | 230.97 (277.92, 315.81)  | 0.93  |
| Cortical thickness (mm) | 4.83 (4.43, 5.23)   | 5.19 (4.79, 5.59)   | 0.07  |
| Marrow area (mm²) | 78.12 (62.24, 94.11)  | 65.89 (51.68, 80.11)  | 0.24  |
| Density          |               |                  |       |
| Cortical BMC (mg) | 248.64 (228.68, 268.60) | 259.94 (239.98, 279.87) | 0.05  |
| Cortical vBMD (mg/cm³) | 1113.54 (1094.40, 1132.69) | 1131.88 (1112.73, 2151.02) | 0.09  |
| Trabecular vBMD (mg/cm³) | 246.78 (226.26, 267.30) | 250.92 (232.70, 269.13) | 0.60  |
| Strength         |               |                  |       |
| pSSI (mm³)       | 789.19 (416.41, 1116.97) | 674.53 (301.75, 1047.31) | 0.41  |
| BMC/muscle CSA (mg/mm²) | 0.043 (0.040, 0.047)   | 0.048 (0.045, 0.052)   | 0.02  |

Adjusted mean (5th, 95th CI). MANCOVA adjusted for height and Tanner stage.
tal findings but did predict alterations in the GH/IGF-1 axis. Lower IGF-1 and greater IGFBP-1 and -5 relative to IGF-1 levels were predicted by poor metabolic control, whereas a higher IGFBP-1/IGF-1 ratio was predictive of smaller, less mineralized bones. Increased urine magnesium loss was associated with decreased stature and linear growth in T1DM. Magnesium depletion in animals is characterized by impaired bone growth, decreased osteoblast number, increased osteoclast number, and loss of trabecular bone. Microalbuminuria is associated with greater urine magnesium loss and lower serum 25(OH) vitamin D levels in adolescents and young adults with T1DM. Our T1DM cohort was prescreened to rule out the presence of microalbuminuria to help exclude subjects with diabetic nephropathy. Diabetic microangiopathy, however, seems to precede the elevation of albumin excretion by 3 yr in adolescents with T1DM. Despite serum glucose levels below the renal threshold to elicit glucosuria (<200 mg/dl), greater urine magnesium loss was associated with elevated serum glucose levels in this study. Therefore, greater magnesium excretion may reflect subtle changes in renal tubular function and/or glucosuria, which subsequently impaired skeletal growth in our T1DM subjects.

The cross-sectional design and pubertal maturation range of our study population limit the interpretation of our results. Although we attempted to compensate by using pubertal stage–matched controls, the majority of subjects were in the later phase of puberty, when most pubertal-driven skeletal growth has occurred but before completion of skeletal mineralization. Whereas the GH-IGF axis abnormalities in diabetes are well characterized, there is little understanding of how these abnormalities effect skeletal growth at the tissue level. IGFBPs profiles are tissue specific, and serum IGFBPs measurements may not reflect their modulation of IGF-1 in bone. Furthermore, we did not separate the effects of estrogen on the GH-IGF axis, both of which contribute to skeletal growth and mineralization during puberty.

In summary, poor metabolic control predicted alterations in the GH/IGF-1 axis and IGFBP levels, whereas greater urine magnesium excretion predicted variations in bone geometry and density in adolescent girls with T1DM. Additional studies are needed to gain insights about bone formation and its dysregulation in pubertal children with T1DM.

ACKNOWLEDGMENTS

This work was funded by the Primary Children’s Foundation and Grant M01-RR00064 from the National Center for Research Resources.

REFERENCES

1. Leidig-Bruckner G, Ziegler R 2001 Diabetes mellitus: a risk for osteoporosis? Exp Clin Endocrinol Diabetes 109(Suppl 2):S49–S54.

2. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, Serrano Pardo MD, Garcia-Cervigon AG 2000 Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: A prospective study. Osteoporos Int 11:455–459.

3. Gunczler P, Lanes R, Paz-Martinez V, Martins R, Esaa S, Colmenares V, Weisinger JR 1998 Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatri Endocrinol Metab 11:413–419.

4. Gunczler P, Lanes R, Paoli M, Martinin R, Villarol E, Weisinger JR 2001 Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. J Pediatri Endocrinol Metab 14:525–528.

5. Erozy B, Goeksen D, Darcan S, Mavi E, Ozturk C 1999 Evaluation of bone mineral density in children with diabetes mellitus. Indian J Pediatri 66:375–379.

6. Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A 2002 The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with Type 1 diabetes mellitus. Horm Res 58:266–272.

7. Bechtold A, Dirlenbach I, Raile K, Noelle V, Bonfig W, Schwarz HP 2006 Early manifestations of Type 1 diabetes in children is a risk factor for changed bone geometry: Data using peripheral quantitative computed tomography. Pediatrics 118:e27–e634.

8. Heap J, Murray MA, Miller SC, Jalili T, Moyer-Mileur LJ 2004 Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. J Pediatri 144:56–62.

9. Moyer-Mileur LJ, Dixon SB, Quick JI, Askew W, Murray MA 2004 Bone mineral acquisition in Type 1 diabetic adolescents. J Pediatri 145:662–669.

10. Kayath MJ, Dib SA, Vieia JG 1994 Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabetes Complications 8:79–104.

11. Leitgen B, Hauffa B, Mohlmann C, Jeken C, Reiners C 1995 Bone mineral density in children and adolescents with juvenile diabetes: Selective measurement of bone mineral density of trabecular and cortical bone using peripheral quantitative computed tomography. Horm Res 43:173–175.

12. Bonfanti R, Mora S, Principi C, Bognetti E, Meschi F, Pazzovio M, Proverbio MC, Chiumello G 1997 Bone modeling indexes at onset and during the first year of follow-up in insulin-dependent diabetic children. Calcif Tissue Int 60:397–400.

13. Kemink SA, Herms AR, Swinkels LM, Lutterman JA, Smals AG 2000 Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23:295–303.

14. De Schepper J, Smits J, Rosseneu S, Bollen P, Louis O 1998 Lumbar spine bone mineral density in diabetic children with recent onset. Horm Res 58:193–196.

15. Van Wyk JJ, Smith EP 1999 Insulin-like growth factors and skeletal growth: Possibilities for therapeutic interventions. J Clin Endocrinol Metab 84:4349–4354.

16. Yaker S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D 2002 Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110:771–781.

17. Mohan S, Baylink DJ 2002 IGF-binding proteins are multi-functional and act via IGF-dependent and -independent mechanisms. J Endocrinol 175:19–31.

18. van Coeverden SCCM, Netelenbos JC, de Ridder CM, Roos JC, Popp-Nijders C, Delemarre-van de Waal HA 2002 Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf) 57:107–116.

19. Crowne EC, Samra JS, Cheetham T, Acrerini CL, Watts A, Holly JM, Dunger DB 2001 The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus. J Clin Endocrinol Metab 86:3666–3691.

20. Holt RI, Simpson HL, Sonksen PH 2003 The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 20:3–15.

21. Bercetek A, Lang CH, Wilson TA 1999 Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res 31:172–181.
22. Mercado M, Baumann G 1995 Characteristics of the somatotropic axis in insulin dependent diabetes mellitus. Arch Med Res 26:101–109.
23. Tanner JM, Whitehouse RH 1976 Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51:170–179.
24. Rockett HR, Wolf AM, Colditz GA 1996 Development and reproducibility of a food frequency questionnaire to assess diets of older children and adolescents. J Am Diet Assoc 95:336–340.
25. Aaron DJ, Kriska A, Dearwater DR, Cauley JA, Metz KF, LaPorte RE 1995 Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activities. Am J Epidemiol 142:191–201.
26. Ainsworth BE, Haskell W, Leon AS, Jacobs DR, Montoye HJ, Sallis JF, Paffenbarger RS Jr 1993 Compendium of physical activities: Classification of energy cost of human physical activities. Med Sci Sport Exer 25:71–80.
27. Ferretti JL, Cointry GR, Capozza RF, Frost HM 2003 Bone mass, bone strength, muscle-bone interactions, osteopenias and osteoporoses. Mech Ageing Dev 124:269–279.
28. Norman TL, Vastishth D, Burr D 1995 Fracture toughness of human bone under tension. J Biomech 28:309–320.
29. Moyer-Mileur L, Xie B, Ball S, Bainbridge C, Stadler D, Jee WS 2001 Predictors of bone mass by peripheral quantitative computed tomography in early adolescent girls. J Clin Densitom 4:313–323.
30. Molgaard C, Thomsen B, Michaelsen KF 1998 Influence of weight, age, and puberty on bone size and bone mineralization in childhood and adolescents. Acta Paediatr 87:494–499.
31. Katzman D, Bachrach L, Carter D, Marcus R 1991 Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. J Clin Endocrinol Metab 73:1332–1339.
32. Center for Disease Control. Epi Info 2000 A Data and Statistics Program for Public Health Professionals for Use on Windows. Epi Info, Atlanta, GA, USA.
33. Libanati C, Baylink DJ, Lois-Wenzel E, Srinivasan N, Mohan S 1999 Studies on the potential mediators of skeletal changes occurring during puberty in girls. J Clin Endocrinol Metab 84:2807–2814.
34. Halldin MU, Tylleskar K, Hagenas L, Tuvebo T, Gustafsson J 1998 Is growth hormone hypersecretion in diabetic adolescent girls also a daytime problem? Clin Endocrinol 48:785–794.
35. Thrailkill KM 2000 Insulin-like growth factor-I in diabetes mellitus: Its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther 2:69–80.
36. Liu WY, Wactawski-Wende J, Donahue RP, Dmochowski J, Hovey KM, Quatrin T 2003 Does low bone mineral density start in post-teenage years in women with Type 1 diabetes? Diabetes Care 26:2365–2369.
37. Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W 2005 Elevated hip fracture risk in type 1 diabetic patients. Diabetes Care 28:2850–2855.
38. Rude RD, Gruber HE, Woi LY, Frausto A, Mills BG 2003 Magnesium deficiency: Effect on bone and mineral metabolism in the mouse. Calcif Tissue Int 72:32–41.
39. Verrotti A, Basciani F, Carle F, Morgese G, Chiarelli F 1999 Calcium metabolism in adolescents and young adults with type 1 diabetes mellitus without and with persistent microalbuminuria. J Endocrinol Invest 22:198–202.
40. Chiarelli F, Pomilio M, DeLuca FA, Vecchiet J, Verrotti A 2001 Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol 16:116–120.

Address reprint requests to:
Laurie J Moyer-Mileur, PhD, RD
PO Box 581289
Salt Lake City, UT 84158, USA
E-mail: laurie.moyer-mileur@hsc.utah.edu

Received in original form February 4, 2008; revised form June 20, 2008; accepted July 25, 2008.